These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23300030)

  • 1. The design and analysis of parallel experiments to produce structurally identifiable models.
    Cheung SY; Yates JW; Aarons L
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):93-100. PubMed ID: 23300030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):279-92. PubMed ID: 21347679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural identifiability of physiologically based pharmacokinetic models.
    Yates JW
    J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):421-39. PubMed ID: 16568353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.
    Galvanin F; Ballan CC; Barolo M; Bezzo F
    J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):451-67. PubMed ID: 23733369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifiability in tracer experiments.
    Cobelli C; Lepschy A; Jacur GR
    Fed Proc; 1980 Jan; 39(1):91-6. PubMed ID: 7351249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifiable pharmacokinetic models: the role of extra inputs and measurements.
    Godfrey KR; Jones RP; Brown RF
    J Pharmacokinet Biopharm; 1980 Dec; 8(6):633-48. PubMed ID: 7229913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.
    Yu LX; Lipka E; Crison JR; Amidon GL
    Adv Drug Deliv Rev; 1996 Jun; 19(3):359-76. PubMed ID: 11540095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.
    D'Argenio DZ
    Math Biosci; 1990 Apr; 99(1):105-18. PubMed ID: 2134510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What do we mean by identifiability in mixed effects models?
    Lavielle M; Aarons L
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):111-22. PubMed ID: 26660913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of gastrointestinal motility directly from human pharmacokinetic data.
    Roush JA
    Int J Pharm; 2011 Oct; 419(1-2):43-51. PubMed ID: 21784142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal experimental requirements for structural identifiability in linear compartmental models. The software 'IDEXMIN'.
    Mérino JA; de Biasi J; Plusquellec Y; Houin G
    Arzneimittelforschung; 1996 Mar; 46(3):324-8. PubMed ID: 8901159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).
    Pang KS
    Drug Metab Dispos; 2003 Dec; 31(12):1507-19. PubMed ID: 14625347
    [No Abstract]   [Full Text] [Related]  

  • 14. A compartmental absorption and transit model for estimating oral drug absorption.
    Yu LX; Amidon GL
    Int J Pharm; 1999 Sep; 186(2):119-25. PubMed ID: 10486429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.
    Eisenberg MC; Jain HV
    J Theor Biol; 2017 Oct; 431():63-78. PubMed ID: 28733187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat.
    Peters SA; Hultin L
    J Pharmacokinet Pharmacodyn; 2008 Feb; 35(1):1-30. PubMed ID: 17963025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.
    Siripuram VK; Wright DFB; Barclay ML; Duffull SB
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):415-423. PubMed ID: 28612141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically based pharmacokinetic modeling approach.
    Sidhu P; Peng HT; Cheung B; Edginton A
    Can J Physiol Pharmacol; 2011 May; 89(5):365-82. PubMed ID: 21627485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations.
    Lennernäs H
    Mol Pharm; 2009; 6(5):1429-40. PubMed ID: 19655809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.